{"result_id": "159027", "URL": "https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1469-7481", "timestamp": "2023-04-25 15:31:53 CEST+0200", "meta": {"description": "", "lang": "de", "keywords": "", "favicon": "/products/assets/mobile/img/h/apple-touch-icon-3cbb7a2b0635c836ae6c379dc18f83df.png", "canonical": "https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1469-7481", "encoding": "utf-8"}, "image": null, "domain": "www.thieme-connect.com", "title": "Thieme E-Books & E-Journals", "cleaned_text": "The COVID-19 pandemic is an ongoing global healthcare crisis. Based on reports of atypically located thromboses following vaccination with the AstraZeneca COVID-19 vaccine, the Society of Thrombosis and Haemostasis Research (GTH) has issued guidance statements on the recognition, diagnosis, and treatment of this rare complication. It shares pathophysiological features with heparin-induced thrombocytopenia (HIT) and is referred to as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).\n\nDie COVID-19 Pandemie stellt eine andauernde globale Gesundheitskrise dar. Basierend auf den Berichten \u00fcber atypisch lokalisierte Thrombosen nach Impfung mit dem AstraZeneca COVID-19 Vakzin hat die Gesellschaft f\u00fcr Thrombose- und H\u00e4mostaseforschung (GTH) Handlungsempfehlungen zur Erkennung, Diagnostik und Therapie dieser seltenen Komplikation formuliert. Ihre Pathophysiologie \u00e4hnelt derjenigen der Heparin-induzierten Thrombozytopenie (HIT) und wird als Vakzin-induzierte prothrombotische Immunthrombozytopenie (VIPIT) bezeichnet.", "opengraph": {}, "tags": [], "tweets": [], "movies": [], "links": ["https://www.thieme-connect.de/media/10.1055-s-00034925/202103/lookinside/10-1055-a-1469-7481_210022-1.jpg", "https://doi.org//10.1055/s-0041-1729135"], "authors": ["Cihan Ay", "Manuela Albisetti", "Wolfgang Korte", "Andreas Greinacher", "Vivantes Klinikum im Friedrichshain, Klinik f\u00fcr Innere Medizin Angiologie und H\u00e4mostaseologie, Berlin, Germany", "Institut f\u00fcr Immunologie und Transfusionsmedizin, Universit\u00e4tsmedizin Greifswald, Greifswald, Germany", "Bernd P\u00f6tzsch", "Johannes Oldenburg", "langer@uke.de", "Zentrum f\u00fcr Onkologie, II. Medizinische Klinik und Poliklinik, Universit\u00e4tsklinikum Eppendorf, Hamburg, Germany", "Zentrum f\u00fcr Labormedizin, H\u00e4mostase- und H\u00e4mophilie-Zentrum, H\u00e4matologisches Ambulatorium, St. Gallen, Switzerland", "Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany", "Universit\u00e4tsmedizin Mainz, III. Medizinische Klinik/H\u00e4matologie/CTH, Mainz, Germany", "R\u00fcdiger E. Scharf", "Institut f\u00fcr Transplantationsdiagnostik und Zelltherapie/H\u00e4mostaseologie, H\u00e4motherapie und Transfusionsmedizin, Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany", "Universit\u00e4ts-Kinderspital Z\u00fcrich, H\u00e4matologie, Z\u00fcrich, Switzerland", "Charis von Auer", "Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria", "Florian Langer", "Robert Klamroth"], "publish_date": null}